<DOC>
	<DOCNO>NCT01877668</DOCNO>
	<brief_summary>This 12 month study investigate effectiveness safety tofactinib treat sign symptom , improve physical function preserve bone structure patient active psoriatic arthritis inadequate response traditional , non-biologic disease modify anti-rheumatic drug . Adalimumab use comparator .</brief_summary>
	<brief_title>Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis : Comparator Study</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Males female , age &gt; = 18 year time consent . Have diagnosis Psoriatic arthritis ( PsA ) &gt; = 6 month Meet Classification Criteria PsA ( CASPAR ) time screen Must adequately treat traditional nonbiologic disease modify antirheumatic drug ( DMARD ) . Concurrent treatment methotrexate , leflunomide , sulfasalazine allow require Must take biologic Tumour Necrosis Factor Inhibitor Must 3 swollen joint AND 3 tender joint Must active psoriasis skin lesion Have nonplaque form psoriasis , eg erythrodermic , guttate pustular , exception nail psoriasis allow Pregnant breast feeding , females childbearing potential use highly effective contraception New York Heart Association Class III IV congestive heart failure History hypersensitivity infusion reaction biologic agent Infection HIV , hepatitis B virus , hepatitis C virus , chronic infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>psoriatic arthritis</keyword>
	<keyword>radiographic change</keyword>
	<keyword>active comparator</keyword>
	<keyword>tofacitinib</keyword>
</DOC>